Pharma BD Deal Intelligence
BioPharma-Reporter (citing analyst commentary) suggested the rumored Pall deal could spark a wider M&A flurry across bioprocess tools, anticipating subsequent…
Seeking Alpha note: Evercore ISI's Ross Muken described filtration and separations as 'highly attractive,' with appealing reach in high-growth markets and…
BioProcess Insider's retrospective: combining Pall (acquired 2015) with Cytiva (acquired 2019) created a ~$7.5B-revenue bioprocess juggernaut — validating the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Danaher acquired Pall Corporation for approximately $13.6B in cash, expanding bioprocess filtration and life sciences tools platform. Pall later combined with Beckman/Leica/SCIEX/Molecular Devices to form Danaher's life sciences segment, which spun off as Veralto/Envista components. Borderline pharma BD — included as platform/diagnostics-level life sciences.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Danaher Corporation / Pall Corporation (this deal) | 2015 | $13.6B | 77 |
| Danaher Corporation / Abcam PLC | 2023 | $5.7B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
← Browse all deals · How we score deals
More: 2015 deals · Danaher Corporation deals · Other deals